(NASDAQ: CAPR) Capricor Therapeutics's forecast annual revenue growth rate of 157.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Capricor Therapeutics's revenue in 2026 is $11,130,509.On average, 12 Wall Street analysts forecast CAPR's revenue for 2026 to be $4,596,992,661, with the lowest CAPR revenue forecast at $0, and the highest CAPR revenue forecast at $12,241,121,681. On average, 8 Wall Street analysts forecast CAPR's revenue for 2027 to be $6,422,531,368, with the lowest CAPR revenue forecast at $2,840,580,289, and the highest CAPR revenue forecast at $10,400,038,693.
In 2028, CAPR is forecast to generate $8,776,575,646 in revenue, with the lowest revenue forecast at $4,260,870,433 and the highest revenue forecast at $15,221,051,882.